ABT seems over sold and at a PE of under 30 this
stock is dirt cheap wonder why it has no support but
the analysts are waiting for the earnings and once
they are in the stock will go past 58 and much higher
before the year end.
Your points are well taken. ABT's single digit
growth is a direct result of poor management decisions
by Duane Burnham, particularly the contentious
relationship with the FDA and the Takeda relationship -
Burnham was reportedly unhappy with Takeda back in the
Other health care companies
have similar affirmative action programs, but they
made better strategic decisions to keep up their
double digit internal growth rates. I thought it was
interesting that a prior internal poster said that Burnham
wasn't even listed as a retiree on some internal listing
of them but that Hodgson was. It appears that the
BOD figured out that his risk-averse strategy sold
them all short.
When did you arrive in this country ... and from
which planet? Remember "all men are created
"three civil rights activists killed in Mississippi
....... were registered Republicans" Who cares - they
were LIBERALS or they wouldn't have been there! Yes,
Sellhi, there were liberal Republicans then and there are
a lot more than you think, now.
the standards of law to your utopian vision" My
utopian vision, hah! You are living in a utopian dream
about "Standards of law" when so many states and cities
are having to deal with racial profiling? Lets deal
with reality, Sellhi.
drug firms I think you'll find that they also
support affirmative action, so what is the point? If they
did better its because they made the right decisions
while Abbott made the wrong ones. Abbott's poor
performance in the last year and a half has to do with
decisions made years ago re: the FDA by past and present
senior management who are not minorities last time I
looked. They also screwed up the relationship with Takeda
and their growth strategy seems questionable at best.
TAP has its own problem with Uprima and none of these
problems have anything to do with affirmative
Affirmative action should not be a subject for this board
except to say that we're pleased Abbott has a good
reputation. That should have been the end of the subject
months ago except a core group of arch conservatives has
to blame someone, so why not do the same old thing
and blame the minorities for everything.
worked at Abbott with people of many races and creeds
and religions .... and women, too. Some were better
than I and some weren't. Possibly some were promoted
because of affirmative action, but I'll tell you this -
they were held accountable and either performed or
they were pushed aside. The people who continually
grouse about affirmative action should take their
Bocabergs, do me a favor and look at the growth
charts for the past 2 years of Abbott and compare them
to growth in other pharmaceuticals companies.
Investors want returns. Maybe Abbott shouldn't be so
concerned with earning community respect, I'd rather see
Just remember that Sellhi brought this subject up
from nowhere AGAIN.
Why does it stick in your
craw that Abbott has earned the respect of the
community by trying its best to be an equal opportunity
Plutothecat_17, your ramblings never fail
to make a great case for voting Democratic.
My inside source tells me third quarter earnings
are THE measuring stick for Miles' performance and
future as CEO.
If ABT stock is currently cheap,
it's only because large house investors are hedging
their bets by acting cautiously. They're doing the
For what reasons are the third qtr. results going
to be so important? What drivers exist for a return
to double digit earnings growth at that time? Or is
there another reason (like them holding Miles to his
word perhaps)? If your source is on target, the 3rd
qtr. announcement should be quite interesting.
The whole drug sector has been under pressure.
Abbott has held up well. From a low of $28 to $46.25 is
pretty good. I have been predicting $60 by end of year
for several months now. IMHO Abbott has alot going
for it with the approval of Kaletra, there joint
venture with TAP and you are right a PE under 30. With a
PE of 35 on next year projected earnings of over $2
that would be a price of $75. Long & strong!